Drug and Therapeutics Bulletin 2004;42:89-93; doi:10.1136/dtb.2004.421289
Copyright © 2004 by the BMJ Publishing Group Ltd.

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation

What's wrong with prescribing hypnotics?

Relevant BNF section: 4.1.1

Expert bodies have long advised that use of hypnotic drugs should be limited to short courses for acutely distressed patients and should generally be avoided in elderly people.^1–3 Despite this, more than 10 million prescriptions for hypnotics continue to be dispensed each year in England alone, mostly for benzodiazepines and drugs with similar actions such as zaleplon, zolpidem and zopiclone (so called 'Z-drugs').⁴ Around 80% of all such prescriptions are for people aged 65 years or over,⁵ and many patients remain on the drugs for months or years.⁶ Such prescribing carries many potential hazards for patients, including risk of dependence, accidents and other adverse effects on health.⁷ Here we review how the risks from hypnotic drugs can be minimised.